Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex

This article was originally published in The Pink Sheet Daily

Executive Summary

Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.

You may also be interested in...



Sanctura Once-Daily NDA Touts “Landmark Tolerability”

Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.

Sanctura Once-Daily NDA Touts “Landmark Tolerability”

Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.

Sanctura Co-Promotion Deal

Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel